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Case 1
Patient 1 is a 67-year-old woman with 
unexplained normocytic anaemia on routine 
blood tests. Her white blood cell (WBC) 
count is 9 × 109/L (normal range 4.5 - 11 × 
109/L; normal WBC count differential), 
Hb 10 g/dL (normal range 14 - 18 g/dL), 
mean corpuscular volume 90 fl (normo cytic) 
and platelet count 560 × 109/L (normal range 
150 - 450 × 109/L). Electrolytes, renal and 
liver function are within normal limits. 
C-reactive protein is elevated (30 mg/L; 
normal <5 mg/L), total protein 96 g/L 
(normal range 60 - 80 g/L) and quantitative 
immuno globulins demonstrate an IgG of 
24 g/L (normal range 6.9 - 16.2 g/L), with 
normal IgM and IgA levels. 
Case 2
Patient 2 is a 78-year-old man with back 
pain and an osteolytic vertebral lesion on 
skeletal survey. His WBC count is 11 × 109/L, 
Hb 10 g/dL and platelet count 278 × 109/L. 
His renal function is normal (creatin ine 
70 µmol/L; normal range 44 - 106 µmol/L). 
Serum protein electrophoresis (SPEP) 
demonstrates a monoclonal protein of 10 g/L, 
which is identified on immunofixation as 
IgG kappa. 
Case 3
Patient 3 is a 65-year-old man with anaemia 
(Hb 9 g/dL), hypercalcaemia (3.2 mmol/L; 
normal range 2.1 - 2.6 mmol/L) renal impair-
ment (creati nine 400 µmol/L), and back pain, 
with lytic lesions on X-ray imaging of the 
lumbar spine. SPEP and immunofixation are 
negative. 
Do these patients have evidence of a mono-
clonal protein? Is additional testing required?
What is a monoclonal 
protein?
Testing for monoclonal proteins is indicated 
in the work-up for multiple myeloma or 
other plasma cell disorders. Many synonyms 
of monoclonal proteins exist, including 
M-protein, M-spike, M-band, monoclonal 
immunoglobulin, monoclonal gammopathy 
and paraprotein. A monoclonal protein 
is a unique immunoglobulin secreted by 
identical but abnormal plasma cells that are 
clones of a parent cell. The categorisation 
of the monoclonal protein depends on 
its components: the protein can be an 
immunoglobulin with both a heavy chain 
(IgG, IgA, IgM) and light chain (kappa (κ), 
lambda (λ)), or an isolated light chain (without 
its heavy-chain counterpart) referred to as a 
free light chain (FLC) (Fig. 1). 
The critical first step in interpreting a 
monoclonal protein investigation involves 
confirmation of clonality. An elevated total 
protein level, or an increase in quantitative 
immunoglobulins (IgG, IgA, IgM), is not 
necessarily a clonal process. A polyclonal 
increase in serum immunoglobulins is common 
with liver disease, infection, inflammation 
and other reactive causes. 
How do I test for 
the presence of a 
monoclonal protein?
Serum protein electrophoresis 
SPEP separates serum proteins based 
on their size and charge. There are two 
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Fig. 1 (A). IgG antibody with both heavy and light chains. When the light chain is bound to the heavy 
chain the free light-chain (FLC) epitope is hidden and therefore unable to bind in the serum FLC 
immunoassay. (B) FLCs. When dissociated from its heavy chain counterpart, an epitope is exposed that 
allows binding in the serum FLC assay.
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major types of proteins in the blood: 
albumin and globulin. Globulins can be 
subdivided into alpha-1, alpha-2, beta-1, 
beta-2 and gamma globulins, each with 
distinct electrophoretic properties. A 
homogenous spike in the gamma globulin 
region suggests a monoclonal gammopathy 
(Fig. 2).[1] Importantly, SPEP quantifies the 
size of the monoclonal protein, but does 
not describe the type of protein (i.e. IgG 
kappa, IgA lambda). SPEP is insensitive 
to small monoclonal proteins and should 
therefore be accompanied by serum 
immunofixation.[2,3] 
Serum immunofixation
Serum immunofixation is a complementary 
test to SPEP that is used to further characterise 
a suspected monoclonal protein. Antibodies 
directed against the different heavy- and 
light-chain subtypes result in distinct bands 
that allow identification of the clonal protein 
(Fig. 2). Immunofixation describes the type 
of monoclonal protein (e.g. IgG kappa) and 
has increased sensitivity (~10 ×) for detection 
of small monoclonal proteins not otherwise 
identified on protein electrophoresis.[4] 
Serum free light-chain assay 
While an SPEP is commonly regarded as 
the screening tool for multiple myeloma, 
15 - 20% of patients with this condition 
will not be diagnosed when an SPEP 
is ordered in isolation.[5] A serum FLC 
assay should be performed in addition 
to an SPEP and immunofixation, as the 
combination is highly sensitive to detect 
monoclonal light chains that would 
otherwise be missed by routine serum 
immunofixation techniques.
The serum FLC assay detects FLCs (e.g. 
Bence Jones proteins) using an automated 
immunoassay that reacts against epitopes 
normally hidden when bound to a heavy 
chain (Fig. 1). Interpretation of the serum 
FLC assay requires three parts: quantitative 
measurement of the kappa (normal range 3.3 
- 19.4 mg/L) and lambda (normal range 5.7 
- 26.3 mg/L) FLC levels, and calculation of 
the FLC ratio (kappa/lambda; normal range 
0.26 - 1.65). In the presence of a plasma cell 
disorder, the clonal plasma cell population 
can disproportionately secrete either kappa 
or lambda FLCs, which will markedly alter 
the FLC ratio.
This ratio is critically important to the 
interpretation of FLC testing. States of 
polyclonal hypergammaglobulinaemia, such 
as infection and inflammation (increased 
production) and renal impairment (reduced 
renal clearance), can result in mild to modest 
elevations in FLCs.[6-8] However, in these 
instances, the FLC ratio is only minimally 
impacted. In chronic kidney disease, a 
‘renal range’ of FLC ratio elevation has been 
defined (range 0.37 - 3.1), although it is 
important to emphasise that ratio alterations 
beyond this require further investigation, 
regardless of kidney function.[9] 
Is urine protein electrophoresis 
testing ready for retirement? 
Historically, urine protein electrophoresis 
(UPEP) and immunofixation were used 
to increase the sensitivity of monoclonal 
protein detection. The requirement for 
a 24-hour urine collection and lack of 
sensitivity to low levels of abnormal FLCs 
generated enthusiasm to replace UPEP with 
the serum FLC assay. The combination of 
SPEP with immunofixation and serum FLC 
testing has sufficient sensitivity to negate 
the need for routine urine testing when 
screening for a monoclonal protein.[10,11] 
The International Myeloma Working Group 
(IMWG) recommends that a serum FLC 
assay replace 24-hour urine immunofixation 
when screening for plasma cell disorders 
(with the notable exception of amyloid light-
chain (AL) amyloidosis).[12,13] While somewhat 
controversial, once a monoclonal protein is 
identified, one could consider using a 24-hour 
UPEP with immunofixation to evaluate 
for potentially nephrotoxic concentrations 
of urinary light chains, although in the 
absence of renal impairment this is unlikely 
to change clinical management.
What disorders 
are associated with 
monoclonal proteins?
Monoclonal proteins are associated with a 
variety of plasma cell disorders, including 
monoclonal gammopathy of undetermined 
significance (MGUS), smoldering multiple 
myeloma, multiple myeloma and solitary 
plasmacytomas. Monoclonal proteins 
are also features of Waldenström macro-
globulinaemia and systemic AL amyloidosis. 
The salient clinical features and test 
abnormalities of these disorders are 
included in Table 1. The vast majority of 
monoclonal proteins ultimately result in a 
diagnosis of MGUS, a premalignant clonal 
condition that increases in frequency with 
age, affects 3% of the population >50 
years of age, and is twice as common in 
patients of African ethnicity.[14,15] MGUS is 
a precursor to conditions such as multiple 
myeloma, AL amyloidosis and Waldenström 
macroglobulinaemia, although the majority 
of patients with MGUS do not develop these 
conditions. Contemporary guidelines do not 
support routine screening for MGUS, as the 
diagnosis does not require specific therapy, 
has been associated with psychological 
harm to the patient, and is associated with 
significant healthcare costs.[16,17] Therefore, 
it is imperative that the decision to pursue 
monoclonal testing be clinically justified 
(Table 1, Fig. 3). 
When should I test for a 
monoclonal protein? 
Monoclonal protein investigations (SPEP, 
immunofixation, and serum FLC assay) 
should be used to identify patients with 
plasma cell disorders (multiple myeloma 
being the most common). Indications to 
order SPEP screening are set out in Table 1 
and Fig. 3. Routine screening with an SPEP 
(or serum FLC assay) is not indicated in the 
absence of signs or symptoms of an associated 
disorder. 
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Fig. 2 (A). Serum protein electrophoresis. Left: a normal electrophoresis pattern. Right: an ‘M-spike’ in 
the gammaglobulin region, which suggests a monoclonal process. Clonality requires confirmation with 
immunofixation. (B) Serum free light-chain (FLC) assay. Normal distribution of kappa (κ) and lambda 
(λ) FLCs are represented in red. Increased FLCs in patients with renal impairment with a preserved FLC 
ratio are depicted in green. A disproportionate increase in lambda FLCs, suggestive of lambda light-
chain multiple myeloma (LCMM), is represented in blue. An increase in kappa light chains, suggestive 
of kappa LCMM, is represented in black. (C) Serum immunofixation. The protein electrophoresis (PEL) 
pattern is included at the top of the image. The monoclonal protein is classified as an IgG kappa based 
on the bands highlighted with immunofixation. (G = IgG; A = IgA; M = IgM; κ = kappa; λ = lambda.) 
Adapted with permission from the American Society of Hematology Self-Assessment Program.[1]
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When a monoclonal protein is identified, investigations should 
be performed to evaluate for associated symptoms. In the case of 
multiple myeloma, the symptoms are classically denoted by the 
acronym CRAB (hyperCalcaemia, Renal impairment, Anaemia, and 
Bone lesions) (Fig. 3). Waldenström macroglobulinaemia, a B-cell 
lymphoproliferative disorder, characterised by the presence of an IgM 
monoclonal protein, requires assessment of lymphadenopathy and 
splenomegaly. AL amyloidosis can result in multi-organ infiltration, 
most commonly affecting the kidneys, liver, heart, gastrointestinal 
tract and peripheral nerves, and therefore warrants a comprehensive 
clinical assessment. 
Cases revisited
Case 1 describes a woman with normocytic anaemia and indices 
suggestive of inflammation (elevated platelet count, C-reactive 
protein and IgG level). While quantitative immunoglobulin tests were 
performed, the patient has not yet had appropriate investigations to 
assess clonality, which would include an SPEP with immunofixation 
and a serum FLC assay.
Case 2 depicts a patient with symptoms of multiple myeloma, 
with an IgG kappa monoclonal protein of 10 g/L identified on 
SPEP and immunofixation. A diagnosis of multiple myeloma was 
confirmed when a bone marrow biopsy demonstrated 16% clonal 
plasma cells. 
Case 3 demonstrates a patient with a high pretest probability of 
multiple myeloma due to the presence of multiple CRAB symptoms; 
yet, the SPEP and immunofixation were negative. This highlights 
the insensitivity of the SPEP and immunofixation in isolation to 
reliably detect the minority of patients who have light-chain disease. 
Further testing with a serum FLC assay is required to complete the 
monoclonal investigation. A practical approach to the evaluation of 
monoclonal proteins is outlined in Table 2.
• Unexplained anaemia
• Osteopenia, osteolytic lesions, spontaneous fractures
• Renal insuciency with bland urinary sediment
• Unexplained proteinuria or Bence Jones proteinuria
When to order an SPEP with immunoxation and serum FLC assay
• Hypercalcaemia with normal PTH
• Hypergammaglobulinaemia
• Immunoglobulin deciency
• Clinical suspicion of AL amyloidosis or Waldenström macroglobulinaemia
Result of SPEP/immunoxation
Polyclonal gammopathy 
(reactive)
Oligoclonal 
gammopathy (usually reactive)
Repeat in 6 - 12 months 
(if clinically indicated)
Monoclonal gammopathy
Assess for CRAB features:
Calcium >2.75 mmol/L or >0.25 mmol/L above normal
Renal: creatinine >177 umol/L or GFR <40 mL/min
Anaemia: Hb <10 g/dL or 2 g/dL below normal
Bone: lytic lesions
• For IgM subtype, assess for lymphadenopathy and splenomegaly
• For AL amyloidosis, assess for multi-organ inltration
Elevated FLC (κ or λ) and 
abnormal ratio (monoclonal)
Investigate for other causes:
• Chronic kidney disease
• Infection
• Inammation
Low-risk MGUS
• Repeat CBC, Cr, SPEP and 
  FLC in 6 months
Not low-risk MGUS
• Consider referral to 
  haematology
Yes
No
Risk stratication:
• IgG M-protein <15 g/L, normal FLC
• IgM M-protein <15 g/L, normal CBC 
  and examination
• κ or λ FLC <100 mg/L
• FLC ratio 0.125 - 8.0
Result of serum FLC assay
Elevated FLC with 
normal ratio (reactive)
 Investigate for other causes:
• Liver disease
• Infection
• Inammation
Refer to haematology
Present Absent
Fig. 3. Interpretation of serum protein electrophoresis and serum free light-chain assay results. (SPEP = serum protein electrophoresis; FLC = free light chain; 
PTH = parathyroid hormone; AL amyloidosis = amyloid light-chain amyloidosis; κ = kappa; λ = lambda; GFR = glomerular filtration rate; 
Hb = haemoglobin; CBC = complete blood count; MGUS = monoclonal gammopathy of undetermined significance; Cr = creatinine.)
Table 1. Typical features of plasma cell disorders associated with a monoclonal gammopathy[18]
Disorder Symptoms Test abnormalities
Low-risk MGUS None IgG M-protein <15 g/L or IgM M-protein <15 g/L with 
normal CBC and examination; kappa or  
lambda FLC <100 mg/L; FLC ratio 0.125 - 8.0
Other MGUS (not low risk) None M-protein <30 g/L, clonal bone marrow plasma cells <10%; 
does not satisfy ‘low risk’ criteria above
Smoldering multiple myeloma None M-protein >30 g/L, clonal bone marrow plasma cells >10%; 
no biomarkers of malignancy*
Multiple myeloma CRAB (hyperCalcaemia, Renal impairment, 
Anaemia, and Bone lesions (related to 
monoclonal protein)
Clonal bone marrow plasma cells >10% or biomarker of 
malignancy
Solitary plasmacytoma Dependent on location of soft tissue or bone 
lesion
Biopsy-proven lesion with evidence of clonal plasma cells;  
no evidence of multiple myeloma otherwise
Systemic AL amyloidosis Can involve multiple organs such as kidney, 
liver, heart, gastrointestinal tract and 
peripheral nerves
Positive amyloid staining by Congo red (any tissue);  
mass spectrometry to confirm amyloid is light-chain related; 
evidence of monoclonal plasma cell disorder
MGUS = monoclonal gammopathy of undetermined significance; CBC = complete blood count; FLC = free light chain; AL amyloidosis = amyloid light-chain amyloidosis.
*Biomarkers of malignancy were incorporated into the most recent criteria for the diagnosis of multiple myeloma. These laboratory abnormalities (clonal bone marrow plasma cells >60%, FLC 
ratio (involved/uninvolved) >100, or >1 focal lesion on magnetic resonance imgaing studies) are associated with an 80% risk of progression to multiple myeloma over a 2-year period, which is felt 
to be sufficient to justify pre-emptive myeloma-directed therapy. 
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Conclusions
In summary, monoclonal protein investigations are indicated in 
the work-up of multiple myeloma and other plasma cell disorders. 
Testing requires confirmation of clonality using an SPEP with 
immunofixation and serum FLC assay. UPEP is no longer required 
as a screening test for monoclonal proteins, with the exception of AL 
amyloidosis. Abnormal results should prompt a clinical evaluation 
for signs and symptoms of disease to distinguish the premalignant 
monoclonal gammopathy of undetermined significance from 
established haematological malignancy. 
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Table 2. A practical approach to monoclonal protein investigation
Does my patient have a clinical presentation warranting a 
monoclonal protein investigation?
• Hypercalcaemia with normal or low PTH
• Renal insufficiency with bland urinary sediment, unexplained proteinuria 
or Bence Jones proteinuria
• Unexplained anaemia
• Osteolytic bone lesions, spontaneous fractures, osteoporosis
• Immune 
• Hypergammaglobulinaemia, immunoglobulin deficiency
• Suspicion for AL amyloidosis or Waldenström macroglobulinaemia
Have I ordered the appropriate tests to assess clonality? • Immunoglobulins
• SPEP: how much?
• Immunofixation: what type?
Have I looked for both monoclonal immunoglobulins and FLCs? • Light chains: serum FLC assay
• Elevations in total protein or quantitative immunoglobulins do not 
confirm clonality (see ‘Polyclonal gammopathy’ in Fig. 3)
If positive, have I looked for consequences of disease? • Hypercalcaemia
• Renal impairment
• Anaemia
• Bone disease
• Lymphadenopathy (IgM subtype)
• Splenomegaly (IgM subtype)
• Multi-organ infiltration (AL amyloidosis)
PTH = parathyroid hormone; AL amyloidosis = amyloid light-chain amyloidosis; SPEP = serum protein electrophoresis; FLC = free light chain. 
